Mulinari, S, Davis, C, Ozieranski, P. “Failure of Responsive Regulation? Pharmaceutical Marketing, Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe”. J. White Collar Corp. Crime 2020:2631309X2097047. SagePub
Ozieranski, P, Csanádi, M, Rickard, E, Mulinari, S. “Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)”. BMJ Open 2020; 10(9):e037351. BMJ
Mulinari, S, Vilhelmsson, A, Rickard, E, Ozieranski, P. “Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs”. PLoS One 2020; 15(6):e0235021. PLoS
Cohen, D, Mulinari, S, Ozieranski, P. “The whistleblowing drama behind Astellas’s suspension from the ABPI”. BMJ 2019:l4353. BMJ
Ozieranski, P, Csanadi, M, Rickard, E, Tchilingirian, J, Mulinari, S. “Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015”. JAMA Netw. Open 2019; 2(6):e196253. JAMA
Ozieranski, P, Rickard, E, Mulinari, S. “Exposing drug industry funding of UK patient organisations”. BMJ 2019:l1806. BMJ
Rickard, E, Ozieranski, P, Mulinari, S. “Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK”. Health Policy (New. York). 2019; 123(12):1244–1250. Elsevier
Fabbri, A, Santos, A, Mezinska, S, Mulinari, S, Mintzes, B. “Sunshine policies and murky shadows in Europe: Disclosure of pharmaceutical industry payments to health professionals in nine European countries”. Int. J. Heal. Policy Manag. 2018. IJHPM
Mulinari, S, Ozieranski, P. “Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: Analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts”. BMJ Open 2018. BMJ
Dunn, A, Coiera, E, Mandl, K, Bourgeois, F. “Conflict of interest disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency”. Res. Integr. Peer Rev. 2016. RIPR